WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality. This data is from the interim analysis of the Phase 3 ZENITH trial. WINREVAIR is currently approved for PAH patients in functional class II and III. #pulmonaryhypertension #pulmonaryarterialhypertension #PAH #chronicthromboembolicpulmonaryhypertension #CTEPH #knowledgesharing #knowledgeexchange #patientempowerment #patienteducation #allianceforph #organtransplant #organdonation #transplant #lungtransplant HTaPFrance Stichting Pulmonale Hypertensie / PH Association the Netherlands PH Belgium - Pulmonale Hypertensie vzw AIPI Italian Pulmonary Hypertension Association Pulmoner Hipertansiyon ve Skleroderma Hasta Dernegi Hellenic Community for Pulmonary Hypertension Pulmonale Hypertonie E.V. Ieva Plume PHA Polska PHA Japan Alliance for Pulmonary Hypertension Pulmonary Hypertension Knowledge Sharing Platform Merck https://lnkd.in/eYjY9a-7
